Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just had a bloomberg business tweet.
Nice little video about QBot and it's offerings.
99,000 views so far.
The article is about liver cancer and how the state of Texas is trying to tackle the problem.
I was really just highlighting the point below for those interested in NSCI/Glycotest. It's not new info.
'This study is also conducting phase III validation of two biomarker panels for early HCC detection – GALAD and Glycotest – to see if these offer high sensitivity for early-stage HCC.'
Yep - end of Dec per clinical website - still do not understand the article you posted!
We should know if it the trials have gone well in the coming months.
Fingers crossed.
That's one of the problems with NSCI - its so technical you don't know whether its good or bad!!
https://www.frontiersin.org/articles/10.3389/fonc.2022.953933/full
Dr. Amit Singal at UT Southwestern leads the third CAP research project focused on evaluating a blood-based biomarker for risk stratification and early detection of HCC. This study is also conducting phase III validation of two biomarker panels for early HCC detection – GALAD and Glycotest – to see if these offer high sensitivity for early-stage HCC. The hypothesis for this study is that androgens increase risk of HCC and estrogens decrease risk of HCC. Further, this proposal leverages data and samples from THCCC to evaluate the extent to which circulating sex hormones are associated with HCC risk in men and women in a nested case-control study.
I think it was the CE marking for Proaxsis/AZ covid test which was mentioned in the last webinar.
or did they say there will be more news Re Sofant soon - about 6 weeks ago?
oh dear 10% down
say Risked fair value 190p and managed to raise funds for NSCI at 65p
https://netscientific.net/analyst-report/
Risked fair value 190p
RNS OUT
Agreed - hold NSCI and track it and this is the most undervalued I've seen it.
Since PDSB was valued at $17 (when pharma experts were saying it was undervalued) it has only has good news, especially with the efficacy results and FDA fast track so the current price is a madness. Partnership with Merck for Keytruda seems a strong possibility given Keytruda failed clinical trials for monotherapy and they specified the need to find partners to advance this treatment area.
For context, Keytruda is used for other treatments and is one of the most profitable drugs in the world - that news would send PDSB into the stratosphere.
PDSB up 12%
Added more today.
PDSB climbing up again.
Sagetech news: We are proud to announce that SageTech Medical’s innovative waste volatile anaesthetic gas capture device has received the UKCA Mark from the MHRA!
UK Conformity Assessed (UKCA) marking is a mark that indicates conformity with the applicable requirements for products sold within Great Britain.
Thanks to the commitment and hard work of our team, we have been able to reach this significant milestone!
Another ground-breaking solution comes from Q-Bot – who use robots to install underfloor insulation, accessing spaces that would be expensive or impossible to reach with more conventional approaches.
Q-Bot worked with Camden Council to install underfloor insulation in 48 properties. This reduced heat loss by 77% and cold draughts by 32%. Councillor Patricia Callaghan said: What’s not to like about Q-Bot, it’s safe, it’s non-disruptive, it makes people’s houses warmer and it can save on bills.”
https://climatechampions.unfccc.int/uk-social-housing-retrofit-could-help-alleviate-fuel-poverty/
Excellent news from PDSB regarding their universal flu vaccine
today announced an upcoming poster presentation at the 41st annual meeting of the American Society of Virology meeting.
All animals vaccinated with PDS0202 survived a lethal challenge with the H1N1 pandemic strain of influenza, compared to a ~40% survival rate in animals vaccinated with COBRA antigens only and a 0% survival rate in untreated animals.
Cheers.
NSCI's holding is 25.7% of Sofant.
This includes direct investment and clients of EMV capital (I think*), so some of this is not direct investment but would reflect control. I don't know the breakdown of this 25.7% though, but at a guess I would say they own at least 15-20% directly. Ilian Iliev is also on the board of Sofant.
Anyone know what we have in Sofant?
With all the Capital under advisment & with direct, I could never fathom out what we have in proper % terms
Added a few this morning to take my holding over 53k shares.
Proxasis/AZ covid test CE marking news due.
yeah,cracking info on that one.
deserves a cappuccino time.
Glad to hear Sofant is making good progress with its technology.
Is it normal for non listed companies to be doing interviews with proactive or is this a sign of things to come?
Thanks Troajan, great interview. Sofant are fast becoming the most exciting business at NSCI!